by Elena Iemma | Apr 2, 2026 | News
EpiVax Enters its Next Chapter with SV Health Investors EpiVax today announced its acquisition by SV Health Investors (SVHI), a healthcare and life sciences-focused private investment firm. This milestone marks an exciting new chapter and will accelerate further...
by Elena Iemma | Mar 18, 2026 | Blog, Featured
Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy Smart, Risk-Based Immunogenicity Planning Starts Early Unexpected immunogenicity can derail even the most...
by Elena Iemma | Feb 13, 2026 | Uncategorized
Day 1 Afternoon Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins (HCPs): Insights and Case Studies Workshop leaders: Anne De Groot, EpiVax | Ben Gabriel, EpiVax | Marla Abodeely, Sanofi | Vibha Jawa, EpiVax Host cell...
by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Dec 23, 2025 | Blog
EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic At EpiVax, we believe in the power of science to improve human health, but we also recognize that science alone cannot reach every community. That...
